New drug cocktail targets tough lung cancer mutation
NCT ID NCT04526782
First seen Nov 18, 2025 · Last updated May 01, 2026 · Updated 25 times
Summary
This study tests a combination of two targeted drugs, encorafenib and binimetinib, in adults with a specific genetic mutation (BRAF V600E) in advanced non-small cell lung cancer that has spread. The goal is to see how well the drugs shrink tumors and delay cancer growth. About 119 participants will receive the treatment and be monitored for response and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AP-HM Hôpital Nord
Marseille, France
-
AP-HP Hôpital Cochin
Paris, 75014, France
-
AP-HP Hôpital Tenon
Paris, 75970, France
-
Angers - CHU
Angers, France
-
Annemasse - CH
Ambilly, 74100, France
-
Avignon - Institut Sainte-Catherine
Avignon, 84918, France
-
Bordeaux - Institut Bergonié
Bordeaux, France
-
Boulogne - Ambroise Paré
Boulogne-Billancourt, France
-
Brest - CHU
Brest, France
-
CH
Colmar, France
-
CH Le Mans
Le Mans, France
-
CHRU Grenoble
Grenoble, France
-
CHRU de Lille
Lille, France
-
CHU Charles Nicolle
Rouen, France
-
CHU Dupuytren
Limoges, 87042, France
-
CHU Rennes - Hôpital Pontchaillou
Rennes, 35033, France
-
CHU Toulouse - Pneumologie
Toulouse, France
-
Caen - CHU Côte de Nacre
Caen, 14000, France
-
Centre Antoine LACASSAGNE
Nice, France
-
Centre Georges François Leclerc
Dijon, France
-
Centre Hospitalier Général - Pau
Pau, 64000, France
-
Centre Hospitalier Intercommunal de Créteil
Créteil, 94000, France
-
Centre Léon Bérard
Lyon, 69000, France
-
Gustave Roussy
Villejuif, 94805, France
-
Hôpital BICHAT
Paris, France
-
Institut Paoli Calmettes
Marseille, 13273, France
-
La Roche Sur Yon - CH
La Roche-sur-Yon, 85925, France
-
Lyon - URCOT
Pierre-Bénite, France
-
Montpellier - CHRU
Montpellier, 34295, France
-
Mulhouse - GHRMSA
Mulhouse, France
-
Nancy - Institut de Cancérologie de Lorraine
Nancy, France
-
Nouvel Hôpital Civil - Hôpitaux Universitaires de Strasbourg
Strasbourg, 67091, France
-
Paris - Institut Curie
Paris, France
-
Saint Quentin - CH
Saint-Quentin, 02100, France
-
Tours - CHU
Tours, 37000, France
-
Villefranche-Sur-Saône - Hôpital Nord-Ouest
Villefranche-sur-Saône, France
Conditions
Explore the condition pages connected to this study.